A new clinical trial led by researchers at Queen Mary University of London suggests that a single injection given every six months may significantly lower blood pressure over time. The findings, published in JAMA, point to a long-lasting treatment option that could improve how hypertension is managed.
The global study, called KARDIA-2, included 663 adults with high blood pressure that was not well controlled with their usual medications.
Trial Finds Added Benefit Over Standard Treatment
Participants in the trial received an injection of the experimental drug zilebesiran in addition to their existing blood pressure treatments. Researchers found that patients who received the injection alongside standard therapy experienced greater reductions in blood pressure compared to those who stayed on standard treatment alone.
These results could have wide-reaching implications. High blood pressure affects about 1 in 3 adults in the UK and is a major risk factor for serious health problems, including heart attacks, strokes, and death if not properly managed.
Expert Insight on Long-Lasting Treatment
Dr. Manish Saxena, Clinical Co-Director of the William Harvey Clinical Research Centre at Queen Mary University of London and a hypertension specialist at Barts Health NHS Trust, led the UK portion of the study and is a senior author of the publication.
“Hypertension is a global health concern as blood pressure control rates remain poor and is a leading cause of heart attacks and strokes. This study demonstrates the efficacy and safety of zilebesiran, when added to commonly used first line blood pressure lowering drugs. The novelty of this treatment is its long duration; giving just one injection every six months could help millions of patients to better manage their condition.”
How Zilebesiran Works
Zilebesiran is an investigational drug that uses RNA interference technology to reduce blood pressure. It works by blocking the production of a protein in the liver (angiotensinogen), which plays a key role in regulating blood pressure. By lowering levels of this protein, blood vessels are able to relax, leading to reduced blood pressure. The treatment is administered as an injection under the skin.
Next Steps for the Treatment
Researchers are continuing to study zilebesiran in a follow-up Phase 2 trial known as KARDIA-3. This study will explore whether the drug can benefit people who have high blood pressure along with established cardiovascular disease or those at high risk for such conditions.
In addition, a large global outcomes study is planned for later this year. This trial will examine whether the treatment can reduce the risk of major cardiovascular events, including strokes and cardiovascular death.
Funding and Trial Leadership
The research was funded by Alnylam Pharmaceuticals. Barts Health NHS Trust played a key role as a lead site in the trial and was the top enrolling center in Europe.